Basiliximab [basiliximab]
- Terms
-
Simulect
-
CHI 621
SDZ CHI 621
Simulect
A chimeric murine-human monoclonal antibody that functions as an INTERLEUKIN 2 RECEPTOR antagonist by binding to the alpha chain (CD25 ANTIGEN) of the interleukin-2 receptor on the surface of activated T-LYMPHOCYTES. It is used in the prevention of acute graft rejection episodes in patients undergoing renal transplantation.
- DUI
- D000077552 MeSH Browser
- CUI
- M0292349
- History note
- 2019 (1998)
- Public note
- 2019; BASILIXIMAB was indexed under ANTIBODIES, MONOCLONAL and RECOMBINANT FUSION PROTEINS 1998-2018
Allowable subheadings
- AD
- administration & dosage
- AE
- adverse effects
- AN
- analysis
- BI
- biosynthesis
- BL
- blood
- CF
- cerebrospinal fluid
- CH
- chemistry
- CL
- classification
- DE
- drug effects
- EC
- economics
- GE
- genetics
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics
- PD
- pharmacology
- PH
- physiology
- PO
- poisoning
- RE
- radiation effects
- TU
- therapeutic use 1
- TO
- toxicity
- UL
- ultrastructure
- UR
- urine